From Research at med.fsu.edu Wed Sep 9 13:07:37 2020 From: Research at med.fsu.edu (Med Research) Date: Wed, 9 Sep 2020 17:07:37 +0000 Subject: Weekly Funding Opportunities Message-ID: <678887EBDC79FB438BFD062B064C59A401A17096FA@FSUCOM128.med.ad.fsu.edu> Michael J. Fox Foundation: Analysis of Patient Reported Outcomes from Fox Insight Study PROs collected in Fox Insight capture information on the lives experience of Parkinson?s that can transform therapeutic development, clinical care and public policy for people with the disease. Data from tens of thousands of people with and without Parkinson?s participating in the study provides the necessary power to generate new understanding of a heterogeneous disease. Investigators unfamiliar with Parkinson?s who present compelling proposals for methods may be paired with a Parkinson?s expert for contextualizing analysis to clinical practice. The dataset and additional resources are available in the Fox Insight Data Exploration Network (Fox DEN). Competitive applications will focus on studies that achieve one or more of the following goals: * Characterize disease progression for people with Parkinson?s * Evaluate the utility of different instruments and/or instrument sub-items in measuring burden of disease, especially in individuals within the first two (2) years of Parkinson?s diagnosis * Identify the role of pharmacological, medical device and/or non-medical interventions on managing Parkinson?s symptoms and long-term health outcomes * Predict the future health status of participants without Parkinson?s based on disease risk variables and model their likelihood of developing Parkinson?s * Determine elements of disease experience that drive patient preference and risk tolerance * Explore the factors that affect volunteer compliance and completeness of participation in an online study * Determine how economic factors, patient-physician communication and lifestyle factors influence medical treatment and long-term health outcomes in people with Parkinson?s * Analyst?s choice: Researchers can submit their own analysis topics based on available Fox Insight data especially as it relates to longitudinal analyses Pre-proposals due October 22, 2020. Med-RA deadline to receive draft documents: October 12. Michael J. Fox Foundation: Development and Validation of Improved Outcome Measures for Parkinson?s Disease The Michael J. Fox Foundation invites applications for grants to fund the development of objective biomarkers that can support therapeutic development in Parkinson?s disease. Through the Development and Validation of Improved Outcome Measures? grant program, the foundation funds the development of biomarkers that enable researchers to improve definite diagnosis, objectively track disease progression, enrich for subject populations, or more precisely detect a treatment response or target engagement ? biomarkers that would transform clinical trial design and assist in the interpretation of trial results. To that end, the foundation welcomes proposals for studies that develop or validate promising biomarkers of Parkinson?s disease, prodromal biomarkers, biomarkers of phenoconversion, or specific molecular biomarker assays; analyze and derive candidate biomarkers from existing biological datasets; or develop and support remote assessment strategies that could complement in clinic assessments. Grants of up to $750,000 over up to two years will be awarded. Pre-proposals due October 22, 2020. Med-RA deadline to receive draft documents: October 12. PIPETTE Consortium: 4R Tau and Alpha-Synuclein PET Tracer Development The PIPETTE Consortium (Philanthropic Investments in PET TracErs) is a funding partnership formed in 2017 by the Michael J. Fox Foundation and Rainwater Charitable Foundation (conveners of the Tau Consortium). The partnership?s goal is to accelerate the development of novel 4R tau and alpha-synuclein PET tracers for primary non-Alzheimer?s tauopathies, Parkinson?s disease, Lewy body dementia, frontotemporal dementia, and other neurodegenerative diseases. As a collaborative effort of leading non-profit organizations, the PIPETTE Consortium seeks to pool ideas, expertise, and resources to enable improved diagnosis and treatment of multiple disorders. Applications should focus on studies that achieve one or more of the following: * In vivo imaging of brain neurofilaments of 4R tau and alpha-synuclein pathology that could be useful as biomarkers of the presence of disease and disease progression and as pharmacodynamic tools for drug development for tauopathies or synucleinopathies * Structure- and ligand-based drug design approaches that use state-of-art computational methods such as the high resolution Cryo-EM structures of disease-relevant tau and alpha-synuclein fibrils and existing Structure Activity Relationship (SAR) on known tau PET ligands or alpha-synuclein PET ligands that are in development We are especially interested in projects to develop alpha-synuclein and tau tracers in parallel. Total amount available to fund 1-2 year projects, 15% IDC: $1M. Pre-proposals due October 22, 2020. Med-RA deadline to receive draft documents: October 12. Michael J. Fox Foundation: Target Advancement Program MJFF believes that promoting target and pathway validation studies within academic and industry laboratories can bridge the critical gap between basic biology and therapeutic development. Validation efforts should focus on early-stage targets that have previously been implicated in Parkinson?s but have not yet been rigorously tested for their ability to impact disease-relevant outcomes in Parkinson?s model systems. Submitted projects should investigate whether genetic or pharmacological modulation of the target can affect Parkinson?s-relevant biological pathways or phenotypes in model systems that may be predictive of therapeutic efficacy. Applications should focus on studies that achieve one or more of the following goals: * Demonstrate pathological relevance of a target by studying its altered expression, distribution, or function in Parkinson?s-relevant human tissues. * Demonstrate that modulation of the target or pathway in vivo in whole mammalian Parkinson?s models using genetic or pharmacological manipulations yields outcomes predictive of clinical efficacy or relevance in human Parkinson?s disease. * Elucidate target or pathway biology in disease-relevant models, including defining upstream/downstream modifiers and convergence of promising target pathways. Pre-proposals due October 22, 2020. Med-RA deadline to receive draft documents: October 12. Multi-disciplinary Machine-assisted, Genomic Analysis and Clinical Approaches to Shortening the Rare Diseases Diagnostic Odyssey (UG3 / UH3 Clinical Trial Not Allowed) This Funding Opportunity Announcement invites researchers to submit applications for multidisciplinary diagnostic strategies for rare diseases that combine machine-assistance, genomic analysis, and clinical consultation. Of particular importance, these strategies must be able to be adopted and performed at the primary or secondary care levels by front-line healthcare providers and be readily integrated into their clinical care workflow. Due November 12, 2020. Med-RA deadline to receive draft documents: October 29. U.S. Tobacco Control Policies to Reduce Health Disparities (R21 / R01 Clinical Trial Optional) R21 R01 The purpose of these Funding Opportunity Announcements (FOAs) is to support observational or intervention research focused on reducing disparities in tobacco use and secondhand smoke (SHS) exposure in the U.S. Specifically, these FOAs aim to stimulate scientific inquiry focused on innovative state and local level tobacco prevention and control policies. The long-term goal of these FOAs is to reduce disparities in tobacco-related cancers, and in doing so, to promote health equity among all populations. Due November 12, 2020, and on standard dates thereafter. Expires September 8, 2023. Med-RA deadline to receive draft documents for November 12 due date: October 29. New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R01 / R34) R01 (Clinical Trial Required) R34 (Clinical Trial Optional) The purpose of these FOAs is to support the testing of enhanced models of care that optimally integrate HIV, addiction, and primary care services. NIDA is interested in research that addresses gaps related to the delivery of comprehensive, integrated health services to include the full continuum of HIV/AIDS services, addiction prevention and treatment services, and primary care services, with a goal of improving the coordination of care, and improving health outcomes related to HIV and SUD in the US. Due November 18, 2020; August 11, 2021; November 18, 2021; August 11, 2022; November 18, 2022; and August 11, 2023. Med-RA deadline to receive draft documents for November 18 due date: November 5. NIH Blueprint for Neuroscience Research: Functional Neural Circuits of Interoception (R01, Clinical Trial Not Allowed) The goal of this FOA is to enhance our fundamental understanding of interoception with a specific focus on dissecting and determining the function of neural circuits that connects peripheral organs/tissues with the central nervous system (CNS) via peripheral ganglia. For this FOA, interoception science includes studies of the processes by which an organism senses, interprets, integrates, and regulates signals originating from within itself. This FOA encourages projects that combine diverse expertise and use innovative approaches to delineate interoceptive mechanisms at the molecular, cellular, circuitry, functional, and/or behavioral levels. Outcomes of this research will lay a critical foundation for future translational and clinical research on interoception as well as its roles in nervous system disorders. Due December 18, 2020. Med-RA deadline to receive draft documents for November 18 due date: December 7. NCI Research Specialist Awards: Core-based Scientist and Laboratory-based Scientist (R50 Clinical Trial Not Allowed) These Funding Opportunity Announcements (FOAs) invite grant applications for the Research Specialist Award (R50) in any area of NCI-funded cancer research. R50 Core-based Scientist This FOA is specifically for core/shared resource/central scientific support scientists. The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical, or population science cancer research program, but not serve as independent investigators. These scientists, such as researchers within a core/shared resource/central scientific support, are vital to sustaining the biomedical research enterprise. The Research Specialist Award is intended to provide salary support and sufficient autonomy so that individuals are not solely dependent on NCI grants held by others for career continuity. R50 Laboratory-based Scientist This FOA is specifically for laboratory-based scientists. The Research Specialist Award is designed to encourage the development of stable research career opportunities for exceptional scientists who want to continue to pursue research within the context of an existing NCI-funded basic, translational, clinical, or population science cancer research program, but not serve as independent investigators. These non-tenure track scientists, such as researchers within a research program, are vital to sustaining the biomedical research enterprise. It is anticipated that only exceptional scientists who want to pursue research within the context of an existing NCI-funded cancer research program, but not serve as independent investigators, will be competitive for this award. Due January 4, 2021. Med-RA deadline to receive draft documents for November 18 due date: December 14. HIV Vaccine Research and Design (HIVRAD) Program (P01 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to support multi-component, multi-disciplinary projects that address scientific questions relevant to AIDS prophylactic vaccine discovery research. Extensive evaluation of vaccine concepts in non-human primate models may be included. Due March 15, 2021; March 15, 2022; and March 15, 2023. Med-RA deadline to receive draft documents for March 15 due date: March 2. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Mon Sep 21 13:27:47 2020 From: Research at med.fsu.edu (Med Research) Date: Mon, 21 Sep 2020 17:27:47 +0000 Subject: Weekly Funding Opportunities Message-ID: <678887EBDC79FB438BFD062B064C59A401A17411DC@FSUCOM128.med.ad.fsu.edu> Note Regarding NSF Biosketch Requirements: Effective October 5, 2020, the National Science Foundation (NSF) will begin enforcing the Proposal & Award Policies & Procedures Guide (PAPPG) (NSF 20-1) requirement to use NSF-approved formats for the preparation of the Biographical Sketch and Current and Pending Support proposal documents. The NSF-approved formats are SciENcv: Science Experts Network Curriculum Vitae and an NSF fillable PDF. The NSF Biographical Sketch and Current and Pending Support websites include links to the NSF-fillable PDF formats, updated FAQs, and instructions. NIAID Research Education Program (R25 Clinical Trial Not Allowed) The overarching goal of this NIAID R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation?s biomedical, behavioral and clinical research needs of NIAID mission areas. * Courses for Skills Development: It is expected that the course(s) for skills development provide innovative, state-of-the-art, evidence-based education that relates to the mission of NIAID, and is derived from biomedical, behavioral or clinical research findings. For example, advanced courses in a specific discipline or research area, clinical procedures for research, specialized research techniques, or research methodology. The courses may include elements that promote research skills and career skills of the participants. The format of the courses may involve a traditional in-person approach, online activities, a hybrid of both approaches, or other methods. * Research Experiences: It is expected that the research experiences supported by this FOA are relevant to the trainees area of science, yet sufficiently different such that it expands or extends their skills. The expanded experience has to meet the needs and career level of participants. Research experiences must also be designed to address some area of NIAID extramurally supported research. For example, for graduate and health professional students: to provide research experiences and related training not available through formal NIH training mechanisms; to provide hands-on authentic research experiences that reflect ownership of a project and provide opportunity for meaningful contribution to the research in question, and stimulate their interest to consider further education and training for future research related to the NIAID mission; for postdoctorates and junior faculty: to extend their skills, experiences, and knowledge base and prepare them for a NIAID-related career research. * Mentoring Activities: Within the context of a mentoring network activities may include, but are not limited to, dedicated efforts at providing technical expertise, advice, insight, and professional career skills that advance the broad career goals of graduate students, postdoctorates and/or early-career faculty; facilitating scholarly writing and grantsmanship; promoting successful transitions from one career stage to another; providing leadership development; helping to identify potential collaborators; helping to establish interdisciplinary or translational collaborations in order to foster a career trajectory towards independent NIAID-related research. Due December 7, 2020; December 7, 2021; and December 7, 2022. Med-RA deadline to receive draft documents for December 2020 due date: November 23. NSF?s Collaborative Research in Computational Neuroscience (CRNS): Innovative Approaches to Science and Engineering Research on Brain Function Computational neuroscience provides a theoretical foundation and a rich set of technical approaches for understanding complex neurobiological systems, building on the theory, methods, and findings of computer science, neuroscience, and numerous other disciplines. Through the CRCNS program, the U.S. National Science Foundation (NSF), National Institutes of Health (NIH), and Department of Energy (DOE); the German Federal Ministry of Education and Research (Bundesministerium f?r Bildung und Forschung, BMBF); the French National Research Agency (Agence Nationale de la Recherche, ANR); the United States-Israel Binational Science Foundation (BSF); Japan?s National Institute of Information and Communications Technology (NICT); and Spain?s State Research Agency (Agencia Estatal de Investigaci?n, AEI) and National Institute of Health Carlos III (Instituto de Salud Carlos III, ISCIII) support collaborative activities that will advance the understanding of nervous system structure and function, mechanisms underlying nervous system disorders, and computational strategies used by the nervous system. Two classes of proposals will be considered in response to this solicitation: Research Proposals describing collaborative research projects. Data Sharing Proposals to enable sharing of data and other resources. Due December 10, 2020; November 23, 2021; November 22, 2022. Med-RA deadline to receive draft documents for December 2020 due date: November 30. Translational Research in Maternal and Pediatric Pharmacology and Therapeutics (R21 / R01 Clinical Trial Optional) R21 R01 The purpose of these funding opportunity announcements is to encourage applications that will perform basic, translational and clinical research to (1) advance the understanding of underlying mechanisms of drug action; (2) discover and develop novel therapeutics; (3) enhance the usage of existing drugs or drug repurposing for safer and more effective treatment for pregnant women, lactating women, neonates and children. The overall goal is to improve drug safety and efficacy for maternal and pediatric precision therapeutics. Due December 10, 2020; April 9, 2021; August 10, 2021; December 10, 2021; April 11, 2022; August 10, 2022; and December 9, 2022. Med-RA deadline to receive draft documents for December 2020 due date: November 30. BRAIN Initiative: Pilot resources for brain cell type-specific access and manipulation across vertebrate species (U01 Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) from the NIH Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is intended to support the development of technologies, production efforts, and dissemination resources for a cell type-specific armamentarium to study brain function across species. The goal is to promote evaluation of molecular or genetic technologies and creation of pilot production and distribution resources for cell type-specific access and manipulation reagents for several vertebrate species, including in human ex vivo tissues or cells. Demonstration projects are sought that would develop reagents that: (1) enable access to molecularly defined neural cell types in a complex brain region or significant brain network of a vertebrate; (2) are easily produced, disseminated, utilized, and stored; and (3) are catalogued for users in a brain atlas. In addition to the above required features, reagents are also sought that exhibit the following qualities: (4) are applicable to both genetically tractable and less tractable vertebrate organisms; (5) exhibit high specificity and efficiency of targeting; (6) show low toxic or perturbative effects; (7) provide flexibility to deliver various reporter, sensor, and effector payloads and are compatible with other methods of access to brain cell types; and (8) are potentially usable in human ex vivo brain tissue or cells. The pilot projects should be scalable in the future. The long-term goal of a potentially scaled-up effort is to achieve near comprehensive, molecular access for monitoring and manipulation reagents in each defined cell type of vertebrate brains relevant to neuroscience research. Due February 11, 2021 and October 19, 2021. Med-RA deadline to receive draft documents for February 2021 due date: February 1. Social and Behavioral Intervention Research to Address Modifiable Risk Factors for Cancer in Rural Populations (R01 Clinical Trial Required) The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to develop, adapt, and test individual-, community- or multilevel interventions to address modifiable risk factors for cancer in rural populations. Applications should focus on primary prevention and assess and address one or more of the social and behavioral risk factors that contribute to cancer disparities in rural populations: tobacco use; diet, physical activity and weight; alcohol use; UV exposure; and HPV vaccination. Applications should also assess and address myriad social determinants of health, cultural factors, and health care and technology access barriers that may contribute to rural cancer disparities. This FOA also encourages implementation science research, to incorporate efficacious cancer control interventions in a coordinated way, into broader, sustainable health programs that are designed to reach rural populations and allow local customization and adaptation. Due March 15, 2021 and January 18, 2022. Med-RA deadline to receive draft documents for March 2021 due date: March 2. Development of the Fetal Immune System (R01 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement is to understand the contribution of specific elements of maternal molecular and cellular factors that can control and effect the development of the fetal immune system. Due April 7, 2021; December 7, 2021; April 7, 2022; December 7, 2022; April 7, 2023; and December 7, 2023. Med-RA deadline to receive draft documents for April 2021 due date: March 25. Modules for Enhancing Biomedical Research Workforce Training (R25 Clinical Trial Not Allowed) The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation?s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: * Curriculum or Methods Development Specifically, this FOA will support the development of training modules designed to be freely available, at no cost to the broader community to enhance training of the biomedical research workforce. Responsive topics will be indicated through Notices of Special Interest (NOSIs) released annually by NIGMS. Due June 18, 2021; June 20, 2022; and June 19, 2023. Med-RA deadline to receive draft documents for June 2021 due date: June 7. To search for additional funding opportunities, please visit CoM?s unofficial funding opportunities blog. -------------- next part -------------- An HTML attachment was scrubbed... URL: From Research at med.fsu.edu Tue Sep 29 08:22:20 2020 From: Research at med.fsu.edu (Med Research) Date: Tue, 29 Sep 2020 12:22:20 +0000 Subject: Upcoming Webinar for Faculty: Navigating ClinicalTrials.gov Message-ID: <678887EBDC79FB438BFD062B064C59A401A175EBC4@FSUCOM128.med.ad.fsu.edu> Navigating ClinicalTrials.gov When: 10:00 - 11:00 AM, October 21, 2020 Where: Virtual Event (Zoom invite with be sent to registrants) Register Here Are you new to ClinicalTrials.gov and find yourself struggling with how to start and where to go for help? Or do you already have an account but find the website difficult to navigate and the required details daunting? In a collaborative effort, the Office for Clinical Research Advancement (OCRA) and the Office of Research Development (ORD) have developed a workshop for ClinicalTrials.gov users. The workshop will cover creating a ClinicalTrials.gov account for new users, study registration, the PRS review process, and review timelines for study submission/updating. You also will get to hear from a ClinicalTrials.gov user, Human Sciences Associate Professor Michael Ormsbee, on what has helped him ?survive? ClinicalTrials.gov. Attendees are invited to bring their own scenarios for discussion during a Q&A session and should leave the workshop with skills to successfully navigate and manage their studies within ClinicalTrials.gov For webinar questions, please contact Krissy Capitano. For Zoom technology questions, please contact Evangeline Ciupek. -------------- next part -------------- An HTML attachment was scrubbed... URL: